NEW YORK,
Nov. 28,
2023 /PRNewswire/ -- The Gross Law Firm issues the
following notice to shareholders of Outlook Therapeutics,
Inc..
Shareholders who purchased shares of OTLK during
the class period listed are encouraged to contact the firm
regarding possible lead plaintiff appointment. Appointment as lead
plaintiff is not required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/outlook-loss-submission-form/?id=57278&from=4
CLASS PERIOD: December 29, 2022 to August 29, 2023
ALLEGATIONS: The complaint
alleges that during the class period, Defendants
issued materially false and/or misleading statements and/or failed
to disclose that: (i) there was a lack of substantial evidence
supporting the Company's lead product candidate, ONS-5010, as a
treatment for wet age-related macular degeneration; (ii) Outlook
and/or its manufacturing partner had deficient chemistry
manufacturing and controls and other manufacturing issues for
ONS-5010, which remained unresolved at the time the ONS-5010
biologics license application ("BLA") was resubmitted to the U.S.
Food and Drug Administration ("FDA"); (iii) as a result of all the
foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its
present form; (iv) accordingly, ONS-5010's regulatory and
commercial prospects were overstated; and (v) as a result, the
Company's public statements were materially false and misleading at
all relevant times.
DEADLINE: January 2,
2024 Shareholders should not delay in registering for
this class action. Register your information here:
https://securitiesclasslaw.com/securities/outlook-loss-submission-form/?id=57278&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you
register as a shareholder who purchased shares of OTLK during the
timeframe listed above, you will be enrolled in a portfolio
monitoring software to provide you with status updates throughout
the lifecycle of the case. The deadline to seek to be a lead
plaintiff is January 2, 2024. There
is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is
a nationally recognized class action law firm, and our mission is
to protect the rights of all investors who have suffered as a
result of deceit, fraud, and illegal business
practices. The Gross Law Firm is committed to ensuring that
companies adhere to responsible business practices and engage in
good corporate citizenship. The firm seeks recovery on behalf of
investors who incurred losses when false and/or misleading
statements or the omission of material information by a company
lead to artificial inflation of the company's stock. Attorney
advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-outlook-therapeutics-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-january-2-2024--nasdaq-otlk-301998508.html
SOURCE The Gross Law Firm